X
[{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Therapeutics welcomes UK Regulatory Authority approval of Phase 2 clinical trial in critical limb ischaemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Podiatry","graph2":"Preclinical"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Preclinical Study to Investigate the High Potency of Cymerus\u2122 MSCs","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Expands MEND Clinical Trial in Covid-19 and Respiratory Failure","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethics Approval for Cynata\u2019s Clinical Trial in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Podiatry","graph2":"Preclinical"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Treated in Phase 2 GvHD Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Therapeutics Completes Patient Enrolment in Phase 1 Trial of CYP-006TK in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Podiatry","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Cynata Therapeutics
Filters
Companies By Therapeutic Area
Details:
CYP-006TK is a topical wound dressing, cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with diabetic foot ulcers.
Lead Product(s):
CYP-006TK
Therapeutic Area: Podiatry
Product Name: CYP-006TK
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 09, 2024
Details:
CYP-001 is Cynata's Cymerus™ off-the-shelf iPSC[1]-derived MSC[2] product candidate for intravenous infusion, which is being evaluated for the treatment of acute graft versus host disease.
Lead Product(s):
CYP-001,Prednisone
Therapeutic Area: Immunology
Product Name: CYP-001
Highest Development Status: Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 04, 2024
Details:
CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing. It is being evaluated for the treatment of diabetic foot ulcer.
Lead Product(s):
CYP-006TK
Therapeutic Area: Podiatry
Product Name: CYP-006TK
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 26, 2024
Details:
CYP-001 (mesenchymoangioblast-derived mesenchymal stem cells) met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial.
Lead Product(s):
Mesenchymoangioblast-derived Mesenchymal Stem Cells
Therapeutic Area: Immunology
Product Name: CYP-001
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 26, 2022
Details:
This will be the first clinical trial to utilise CYP-006TK, a polymer-coated silicon dressing (seeded with Cymerus MSCs) that Cynata has licensed from TekCyte Pty Ltd (TekCyte).
Lead Product(s):
Cymerus mesenchymal stem cells
Therapeutic Area: Podiatry
Product Name: CYP-006TK
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 30, 2021
Details:
In the initial stage, the trial was designed to assess the early efficacy of Cymerus MSCs in Covid-19 patients admitted to intensive care. The trial will now analyse the early efficacy of Cymerus MSCs in patients with respiratory failure.
Lead Product(s):
CYP-001
Therapeutic Area: Infections and Infectious Diseases
Product Name: Cymerus MSCs
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 29, 2021
Details:
Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing.
Lead Product(s):
Cymerus mesenchymal stem cell
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 02, 2021
Details:
Cynata plans to undertake a clinical trial of its Cymerus MSC product in patients with diabetic foot ulcers based on this solid pre-clinical foundation and utilising the TekCyte technology.
Lead Product(s):
Cymerus mesenchymal stem cell
Therapeutic Area: Podiatry
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 01, 2021
Details:
Treatment with Cynata’s Cymerus MSCs led to statistically significant improvements in multiple harmful effects of IPF, including interstitial fibrosis, dynamic lung compliance and airway resistance.
Lead Product(s):
Cymerus mesenchymal stem cells
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 08, 2020
Details:
The Phase 1 trial, which was the world’s first clinical trial of an allogeneic iPSC-derived MSC product, evaluated the safety and efficacy of CYP-001 for the treatment of patients with steroid-resistant acute graft-versus-host disease (GvHD).
Lead Product(s):
MCA-derived mesenchymal stem cells
Therapeutic Area: Immunology
Product Name: CYP-001
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 30, 2020